Jennison Associates LLC lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,033,376 shares of the medical research company’s stock after acquiring an additional 60,318 shares during the period. Jennison Associates LLC owned about 0.49% of Edwards Lifesciences Corporation worth $112,958,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Sabal Trust CO raised its position in shares of Edwards Lifesciences Corporation by 0.5% during the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after acquiring an additional 14 shares in the last quarter. Alps Advisors Inc. raised its position in shares of Edwards Lifesciences Corporation by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after acquiring an additional 14 shares in the last quarter. Alexandria Capital LLC raised its position in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares in the last quarter. Veritable L.P. raised its position in shares of Edwards Lifesciences Corporation by 1.2% during the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after acquiring an additional 71 shares in the last quarter. Finally, First Bank & Trust raised its position in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock valued at $525,000 after acquiring an additional 76 shares in the last quarter. 82.32% of the stock is currently owned by institutional investors and hedge funds.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $112.45, for a total transaction of $3,699,605.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Larry L. Wood sold 18,960 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total value of $2,119,917.60. The disclosure for this sale can be found here. Insiders have sold a total of 138,580 shares of company stock valued at $15,039,844 over the last ninety days. Company insiders own 2.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/12/jennison-associates-llc-boosts-position-in-edwards-lifesciences-corporation-ew.html.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down $0.93 during trading on Friday, reaching $103.85. The company had a trading volume of 1,728,200 shares, compared to its average volume of 1,916,892. The stock has a market cap of $21,976.74, a P/E ratio of 28.77, a P/E/G ratio of 1.86 and a beta of 0.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corporation has a 1 year low of $81.12 and a 1 year high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.68 earnings per share. research analysts forecast that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.

A number of research analysts recently commented on the company. Canaccord Genuity restated a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Sunday, October 8th. Cowen and Company restated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Thursday, October 12th. Barclays PLC lowered their price objective on Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 25th. BidaskClub downgraded Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $125.17.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.